Results 81 to 90 of about 70,790 (271)

Etanercept In the treatment of AA-amyloidosis in juvenile rheumatoid arthritis

Научно-практическая ревматология, 2004
Objective. To study effect of etanercept, an antagonist of serum A amyloid production in the AA amyloidosis treatment in juvenile idiopathic arthritis (JIA). Material and methods.
H Mihels
doaj   +1 more source

Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD). Calprotectin, an inflammatory biomarker commonly used in IBD, has also been found elevated in psoriasis.
Admir Vižlin, Hans‐Peter Claesson, Ylva Andersch Björkman, Martin Gillstedt, Eva Klingberg, Emanuela Micu, Amra Osmančević   +6 more
wiley   +1 more source

Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial

Pediatric Rheumatology Online Journal
Background Etanercept has been studied in doses up to 0.8 mg/kg/week (max 50 mg/week) in juvenile idiopathic arthritis (JIA) patients. In clinical practice higher doses are used off-label, but evidence regarding the relation with outcomes is lacking.
Bastiaan T. van Dijk, Sytske Anne Bergstra, J. Merlijn van den Berg, Dieneke Schonenberg-Meinema, Lisette W.A. van Suijlekom-Smit, Marion A.J. van Rossum, Yvonne Koopman-Keemink, Rebecca ten Cate, Cornelia F. Allaart, Daniëlle M.C. Brinkman, Petra C.E. Hissink Muller   +10 more
doaj   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Concomitant Treatment with Etanercept and Tacrolimus Synergistically Attenuates Arthritis Progression via Inhibition of Matrix Metalloproteinase-3 Production and Osteoclastogenesis in Human TNF-α Transgenic Mice

Mediators of Inflammation, 2019
In the present study, we investigated the effects and mechanisms of action of a combined treatment with etanercept, a soluble tumor necrosis factor receptor (p75) Fc fusion protein, and tacrolimus, a calcineurin inhibitor on the progression of arthritis ...
Iwao Seki, Miwa Takai-Imamura, Tomomi Kohara-Tanaka, Satoshi Shirae, Minoru Sasano, Hiroaki Matsuno, Hiroyuki Aono   +6 more
doaj   +1 more source

Etanercept in axial spondyloarthritis

, 2022
Gui Luo, Jian Zhu
openalex   +1 more source

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept

mAbs, 2016
A biosimilar is a biological medicinal product that is comparable to a reference medicinal product in terms of quality, safety, and efficacy. SB4 was developed as a biosimilar to Enbrel® (etanercept) and was approved as Benepali®, the first biosimilar of
I. Cho, Nayoung Lee, Dami Song, S. Jung, George Bou-Assaf, Z. Sosic, Wei Zhang, Y. Lyubarskaya   +7 more
semanticscholar   +1 more source

TNF‐α partially modulates the endothelial dysfunction during the acute phase of Trypanosoma cruzi infection

British Journal of Pharmacology, EarlyView.
Background and Purpose Whereas the effects of Trypanosoma cruzi (T. cruzi) infection are well‐characterised in the heart, its impact on the vasculature has received little attention. In this study, we investigated the effects of acute and chronic T. cruzi infection on vascular responsiveness and the underlying mechanisms.
Thales M. H. Dourado, Wanessa M. C. Awata, Gustavo F. Pimenta, Barbara M. Marchetti, Maiara V. Providello, Sérgio De Albuquerque, Carlos R. Tirapelli   +6 more
wiley   +1 more source

Intra-articular vs. systemic administration of etanercept in antigen-induced arthritis in the temporomandibular joint. Part II: mandibular growth

Pediatric Rheumatology Online Journal, 2009
Background Temporomandibular joint (TMJ) arthritis in children causes alterations in the craniomandibular growth. Resultant abnormalities include; condylar erosions, a posterior mandibular rotation pattern, micrognathia, malocclusion with an anterior ...
Gelineck John, Pedersen Thomas K, Küseler Annelise, Kristensen Kasper D, Stoustrup Peter, Herlin Troels   +5 more
doaj   +1 more source

061 What factors predict good patient experiences of switching from reference etanercept to an etanercept biosimilar in a South West London general hospital? [PDF]

, 2018
Laura Attipoe, Samir Patel, Robin Birt, Jennifer Crooks, Kate Hunt, Antigoni Grigoriou   +5 more
openalex   +1 more source